Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B, Chronic | 3 | 2021 | 393 | 0.550 |
Why?
|
| Hepatitis B e Antigens | 2 | 2013 | 133 | 0.550 |
Why?
|
| Guanine | 1 | 2013 | 274 | 0.400 |
Why?
|
| Color | 1 | 2011 | 306 | 0.350 |
Why?
|
| Escherichia coli | 3 | 2011 | 4214 | 0.350 |
Why?
|
| Genes, Bacterial | 2 | 2010 | 1078 | 0.330 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 817 | 0.290 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 808 | 0.290 |
Why?
|
| Antiviral Agents | 3 | 2021 | 2978 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 1032 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 2951 | 0.190 |
Why?
|
| Hemoperitoneum | 1 | 2016 | 40 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2011 | 1871 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5425 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 7153 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1864 | 0.090 |
Why?
|
| Nausea | 1 | 2013 | 665 | 0.090 |
Why?
|
| Nucleotides | 1 | 2013 | 463 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 592 | 0.090 |
Why?
|
| Vomiting | 1 | 2013 | 632 | 0.090 |
Why?
|
| Spleen | 1 | 2016 | 2359 | 0.090 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 513 | 0.090 |
Why?
|
| Community Health Centers | 1 | 2013 | 428 | 0.090 |
Why?
|
| California | 1 | 2013 | 1400 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2016 | 1365 | 0.080 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 859 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2013 | 1059 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3510 | 0.070 |
Why?
|
| Diarrhea | 1 | 2013 | 1343 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 4929 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2010 | 563 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 4771 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1780 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6534 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2010 | 2751 | 0.050 |
Why?
|
| Biopsy | 1 | 2013 | 6756 | 0.050 |
Why?
|
| Prevalence | 1 | 2013 | 15194 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2013 | 77098 | 0.030 |
Why?
|
| Gastric Juice | 1 | 1975 | 64 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 21719 | 0.030 |
Why?
|
| Time Factors | 4 | 2013 | 40054 | 0.030 |
Why?
|
| Adult | 5 | 2021 | 213712 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 213127 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3528 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2013 | 159 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 1975 | 598 | 0.030 |
Why?
|
| Female | 5 | 2021 | 379592 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2013 | 600 | 0.020 |
Why?
|
| Rifampin | 2 | 2008 | 315 | 0.020 |
Why?
|
| Male | 5 | 2021 | 349538 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2013 | 62966 | 0.020 |
Why?
|
| Sulfamethoxazole | 1 | 2008 | 53 | 0.020 |
Why?
|
| Aged | 3 | 2021 | 162944 | 0.020 |
Why?
|
| Ampicillin | 1 | 2008 | 138 | 0.020 |
Why?
|
| Gentamicins | 1 | 2008 | 253 | 0.020 |
Why?
|
| Metronidazole | 1 | 2008 | 217 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 56350 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 2224 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 314 | 0.020 |
Why?
|
| Streptomyces griseus | 1 | 1975 | 6 | 0.020 |
Why?
|
| Hexosaminidases | 1 | 1975 | 54 | 0.020 |
Why?
|
| Digitoxin | 1 | 1975 | 22 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1975 | 70 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 85649 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 175 | 0.020 |
Why?
|
| United States | 1 | 2013 | 69693 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 3913 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 6483 | 0.020 |
Why?
|
| Vancomycin | 1 | 2008 | 500 | 0.020 |
Why?
|
| Humans | 6 | 2021 | 742088 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13256 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 29717 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1978 | 810 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 712 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 1978 | 1319 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12242 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23320 | 0.010 |
Why?
|
| Methods | 1 | 1975 | 1128 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 20928 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 72145 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1975 | 2552 | 0.010 |
Why?
|
| Streptomycin | 1 | 1978 | 69 | 0.010 |
Why?
|
| Ethambutol | 1 | 1978 | 60 | 0.010 |
Why?
|
| Pyrazinamide | 1 | 1978 | 54 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1978 | 637 | 0.000 |
Why?
|
| Isoniazid | 1 | 1978 | 273 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 11 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 223 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 141 | 0.000 |
Why?
|
| Fucose | 1 | 1975 | 125 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 225 | 0.000 |
Why?
|
| Random Allocation | 1 | 1978 | 2425 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1975 | 414 | 0.000 |
Why?
|
| Species Specificity | 1 | 1975 | 2479 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1975 | 3133 | 0.000 |
Why?
|
| Kinetics | 1 | 1975 | 6474 | 0.000 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1978 | 1825 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1978 | 7901 | 0.000 |
Why?
|
| Animals | 2 | 1975 | 168561 | 0.000 |
Why?
|
| Rats | 1 | 1975 | 24265 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1978 | 25575 | 0.000 |
Why?
|
Concepts
(101)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_